Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Company Overview

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Key Stats

• Today's Range: $0.30 to $0.31
• 50-Day Range: $0.30 to $0.38
• 52-Week Range: $0.29 to $4.00
• Volume: 110,820 shs
• Average Volume: 1.21 million shs
• Market Capitalization: $1.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

Cyclacel Pharmaceuticals scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cyclacel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cyclacel Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclacel Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyclacel Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyclacel Pharmaceuticals has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.63% of the float of Cyclacel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclacel Pharmaceuticals has recently decreased by 70.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclacel Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.63% of the float of Cyclacel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclacel Pharmaceuticals has recently decreased by 70.68%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.72

News Sentiment

Cyclacel Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cyclacel Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for CYCC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cyclacel Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,838,865.00 in company stock.

Percentage Held by Insiders

23.97% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

CYCC Stock Analysis - Frequently Asked Questions

How have CYCC shares performed this year?

Cyclacel Pharmaceuticals' stock was trading at $0.3760 at the beginning of the year. Since then, CYCC stock has decreased by 20.5% and is now trading at $0.2990.
View the best growth stocks for 2025 here.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.36. The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative trailing twelve-month return on equity of 1,901.11% and a negative net margin of 18,150.00%.

When did Cyclacel Pharmaceuticals' stock split?

Shares of Cyclacel Pharmaceuticals reverse split before market open on Monday, December 18th 2023. The 1-15 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Cyclacel Pharmaceuticals' major shareholders?

Top institutional investors of Cyclacel Pharmaceuticals include Concourse Financial Group Securities Inc.. Insiders that own company stock include Spiro George Rombotis, Paul Mcbarron and David E Lazar.
View institutional ownership trends.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), General Electric (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 3/29/2025
• Next Earnings (Estimated): 3/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCC
• CIK: 1130166
• Web: www.cyclacel.com
• Phone: (908) 517-7330
• Fax: 866-271-3466
• Employees: 14
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +3,578.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($9.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,560,000.00
• Net Margins: -18,150.00%
• Pretax Margin: -21,390.54%
• Return on Equity: -1,901.11%
• Return on Assets: -188.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.77
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $74,000.00
• Price / Sales: 25.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 6,287,000
• Free Float: 4,780,000
• Market Cap: $1.88 million
• Optionable: Optionable
• Beta: 0.28